Skip to main content
Apeloa Pharmaceutical Co.,Ltd. logo

Apeloa Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 000739 ISIN · CNE000000Q45 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,841 across all filing types
Latest filing 2024-03-07 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 000739

About Apeloa Pharmaceutical Co.,Ltd.

https://www.apeloa.com

Apeloa Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and distribution of active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms. The company operates three core business pillars: API production, Contract Development and Manufacturing Organization (CDMO) services, and finished drug products. Its therapeutic focus includes cardiovascular, anti-infective, anti-viral, and oncology treatments. Apeloa utilizes an integrated supply chain to deliver chemical and biological solutions to a global client base. The organization maintains compliance with international quality standards, including certifications from the FDA, EMA, and PMDA. Its CDMO services encompass the full product lifecycle, from process chemistry and analytical development to large-scale commercial manufacturing, supported by specialized technology platforms such as continuous flow chemistry and enzymatic synthesis.

Recent filings

Filing Released Lang Actions
关于使用自有闲置资金进行理财投资的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from 普洛药业股份有限公司 regarding the use of idle funds for financial investment. It details the investment plan, risk analysis, and control measures, and mentions that the proposal has been approved by the board and will be submitted to the shareholders' meeting for approval. The document is relatively short (1182 characters) and does not contain financial statements or detailed financial data. It is an announcement about a capital management decision rather than a financial report or earnings release. Therefore, it fits best under Capital/Financing Update (CAP).
2024-03-07 Chinese
关于签署战略合作框架协议的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the signing of a strategic cooperation framework agreement between the company and another party. It details the nature of the agreement, the parties involved, the scope of cooperation, and the expected impact on the company's operations. There are no financial statements, quarterly or annual results, or detailed financial data presented. The document is relatively short (4455 characters) and serves as a formal disclosure of a corporate event rather than a financial report or detailed management discussion. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not a regulatory certification or officer attestation. The content is about a strategic partnership agreement announcement, which is best classified under Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit other specific categories.
2024-03-05 Chinese
关于对下属公司担保的进展公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from 普洛药业股份有限公司 regarding the progress of guarantees provided to its subsidiaries. It details specific guarantee contracts, amounts, terms, and the financial status of the guaranteed subsidiaries. The document includes board opinions and cumulative guarantee amounts. It is not a financial report, audit, or earnings release, nor is it a regulatory certification or voting result. It is a regulatory announcement about financing guarantees, which fits best under the category of Regulatory Filings (RNS) as it does not fit other more specific categories like Capital/Financing Update (CAP) because it is more of a progress announcement rather than a financing event or capital structure change. The document length is under 5,000 characters and is a standalone announcement, not a report or presentation. Therefore, the best classification is Regulatory Filings (RNS).
2024-02-29 Chinese
关于公司董事辞职的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of a company director, Mr. Wu Xing, from multiple board and committee positions. It details the resignation date, the impact on the board, and the director's shareholding and compliance commitments post-resignation. There is no financial data, no mention of a report or meeting results, and the content focuses solely on management changes. This fits the definition of 'Board/Management Information' (MANG). The document length is short and it is not a report or announcement of a report publication, so it is not RPA or RNS. Therefore, the classification is MANG with high confidence.
2024-02-27 Chinese
关于对下属公司担保的进展公告
Regulatory Filings Classification · 95% confidence The document is an announcement from 普洛药业股份有限公司 regarding the progress of guarantees provided to its subsidiaries. It details specific guarantee contracts, amounts, terms, and the board's opinion on the guarantees. The document is a formal disclosure about financial guarantees and related risk assessments, not a full financial report or audit. It does not contain comprehensive financial statements or quarterly results but is a regulatory announcement about guarantees. The document length is 3441 characters, which is relatively short and focused on a specific topic. This fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-01-31 Chinese
关于全资子公司终止注射用索法地尔III期临床试验的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from a company about the termination of a Phase III clinical trial for a drug developed by its wholly-owned subsidiary. It details the drug's development history, reasons for termination, and the impact on the company. The document is short (1266 characters) and serves as an official announcement rather than a detailed report or financial statement. It does not contain financial data, audit information, or regulatory certifications. It is not a report publication announcement since it does not mention the release or availability of a report. The content fits best under a Regulatory Filing (RNS) as it is a general regulatory announcement about clinical trial termination and associated risks, which does not fit other specific categories.
2024-01-26 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.